New York – London – Paris
Eric M. Attias
25 year experience
Eric M. Attias, the founder of Forepont, serves as Managing Partner and Chairman of the investment committee. Previously Eric served as Chief Executive Officer, Chief Investment Officer and Board Member of Société Générale Asset Management, Inc (“SGAM”), a wholly owned subsidiary of French banking group Société Générale, which he joined in 2002.
In 2009, Eric co-founded Nexar Capital, a global asset manager, and served as its CIO and as CEO & Board Member of Nexar Capital LLC. Nexar, with offices in New York, London, Jersey and Paris, was acquired by Swiss banking group UBP in 2012.
Eric was then appointed CEO & Board Member of UBP Asset Management LLC and CIO of UBP Alternative Investments.
Prior to SGAM, Eric held senior positions at various Investment Banks. At Dresdner Kleinwort Wasserstein, based in New York, Eric was an EXCO IB member and the Managing Director of the NBG Group. In addition, Eric was the executive board member, CIO and a driving force behind the DrKW Strategic Private Equity fund, investing in Fintech start-ups.
25 year Experience
Mark has over 25 years of experience in the healthcare industry, encompassing operations, commercialization and consulting. He has led some of the largest specialist consulting and communications groups in the world. He founded his own advertising and consulting agency in London. He was COO of EuroRSCG Life (now Havas), Global CEO of healthcare at top brand and business consultancy, Interbrand and Worldwide President of DDB’s (Doyle, Dane and Bernbach) healthcare businesses.
Mark has executed numerous M&A, financing and strategic partnership transactions, (from both sides of the fence), for a broad array of middle market and emerging growth companies in technology, life sciences and healthcare services.
He has a passion for new technology, new “stuff” generally and all things creative. Mark has deep commercial experience working on large, global pharmaceutical, life science and consumer packaged goods brands. He has developed successful commercialization strategies and programs from early-stage and market development, to product launch and late-stage lifecycle management.
Mark began his career as a clinical Pharmacist after obtaining an honors degree in Pharmacy in the UK. He is a Board member of the prestigious Galien Foundation.
Ismail Kola was most recently the Chief Scientific Officer of UCB.
He holds a Ph.D. in Medicine from the University of Cape Town, South Africa. He joined UCB from Schering Plough Corporation where he was Senior Vice President, Discovery Research and Early Clinical Research & Experimental Medicine, Schering-Plough Research Institute, the pharmaceutical research arm of Schering-Plough Corporation, and Chief Scientific Officer, Schering Plough Corporation.
Ismail came to Schering-Plough from Merck, where he was Senior Vice President Basic Research and Site Head, Rahway, Montreal and Madrid. He also chaired Merck’s Antibacterial and Antifungal Worldwide Business Strategy Team.
Prior to that, he was Vice President, Research, and Global Head, Genomics Science and Biotechnology, with Pharmacia Corporation. Prior to his move to Industry, Ismail was Professor of Human Molecular Genetics, Monash University Medical School and Director of the Research Center for Functional Genomics and Human Disease. He was at Monash for approximately 15 years.
Ismail has published 159 papers in top scientific journals which have been cited over 15,000 times and has brought 17 major medicines to market during his 20 year career in the pharmaceutical industry.
He holds Adjunct Professorships of Medicine at Washington University, St Louis, Missouri, USA, and Monash University Medical School, Melbourne, Australia; a Foreign Adjunct Professorship at The Karolinska Institute, Stockholm, Sweden; and is a William Pitt Fellow at Pembroke College, Cambridge University, UK. He is a member of the Board of Athersys Inc., Biotie Therapies, and Astex Pharmaceuticals.
22 year experience
Larry Rubin, is currently seconded to lead Forepont incubated BeCareLink. Together with medical authorities, he created and developed the revolutionary platform that uses Machine Learning techniques to assess patient neurologic functions and clinically significant changes.
Larry, first, worked at Bell Laboratories where he was the co-inventor of a new type of neural network technology.
He, later, founded OuterCurve Technologies Inc which was funded by three public companies.
Larry is, also, the co-founder of Woman’s healthcare venture for detecting breast cancer that is in its 16th year of operation.
Larry has a Master of Philosophy in Computer Science, a MS in Computer Science and a MS in Mathematics from New York University.
15 year experience
Julien brings 15 years of experience in the asset management industry where he has held a variety of senior investor roles for large institutions as well as boutique specialists in the US, France and Switzerland.
After starting his career as an FX trader in San Francisco, Julien became the Head of Alternative Investment & Tactical Asset Allocation for AG2R La Mondiale, one of the largest life insurance companies ($150 bn of assets) in France. He managed the alternative investment portfolio ($1bn) and ran the flagship liquid portfolio ($1.1bn) for over 6 years. He won several awards during that span as top institutional investor and wrote the Guide to Alternative Investments.
In 2015, Julien moved to Switzerland to be a Partner & Managing Director at Trajectoire Capital Group. There he worked with some of the largest European Institutional investors & Family Offices to partner and launch several closed and open-ended funds in different strategies (private equity, venture capital, private debt, insurance claims, distressed real estate, alternative risk premia).
His main focus was on venture capital deals as he directly acquired & strategically developed technology-driven (AI, Machine Learning, Big Data) asset managers in the US and Israel.
Julien holds an MBA from London Business School & Columbia Business School (Dean’s honors) where he focused on private equity, venture capital and entrepreneurship.
He holds a CIIA certification (French Valedictorian) and an Engineering Degree from Aix-Marseille School of Economics in Statistics & Econometrics.
Julien also holds a MSc in Financial Analysis & Investment Management and a Bachelor in Economics from St Mary’s College of California while on a Tennis Scholarship.
He is an Adjunct Professor at Aix-Marseille School of Economics.
18 year experience
Vishal has over 15 years of extensive “blue-chip” investment banking experience, (UBS, Mizuho) and global consulting experience in many industries including medical devices, telecommunication, energy and technology. Vishal has raised over $100 billion in debt and equity capital and has provided strategic advice to large as well as small corporations with respect to M&A, public offerings & capital markets, divestitures and spin-offs.
Vishal has gained an in-depth knowledge of the complex healthcare ecosystem in the United States. He has worked on transactions across multiple sub-sectors of healthcare including large pharma, biotechnology, diagnostics, healthcare instruments and devices, healthcare services and healthcare IT.
He has worked on some of the largest transactions in the healthcare involving Eli Lilly, Abbott Labs, Forest Labs, Actavis, Sigma Aldrich, Schering Plough, Amgen, Hospira and many smaller companies.
Additionally, Vishal has a keen interest in identifying innovative solutions for businesses and homes using combination of technology, healthcare, life sciences and Internet of things (IoT).
Vishal has a degree in Electronics Engineering from the prestigious NIT in India and an MBA from Cornell University.
6 year experience
Youssef joined Forepont and its predecessor firm in 2014, as a senior analyst. He has prior experience in Investment Banking, Private Equity and Venture Capital.
Youssef holds a Master’s degree in finance from the London School of Economics, a Master’s in Management Degree from HEC Paris and a BSc in Economics from the University of Reading (UK).
Bruce has over 25 years of experience in the accounting and finance industry. He is the CFO of Forepont Capital Partners and most of its portfolio companies.
In 2002, he co-founded a Commodity Trading Advisor specializing in commodities and currencies. As its CFO, he executed a strategic partnership with SG Asset Management, Inc.
Later on, Bruce founded his own firm to provide advice to clients in a broad array of industries on matters from tax issues, strategic planning, and mergers & acquisitions.
Bruce holds a BS in accounting from Brooklyn College, CUNY. He obtained his CPA certificate in 1991 and is a member of the AICPA and NYSSCPA.